Letters by company
Kyndryl Holdings, Inc.
4 letters discussing KD. Everything written about it on this site is on its ticker page.
- Royce Investment Partners Royce SMid-Cap Total Return Fund Manager Commentary Royce SMid-Cap Total Return Fund credited Kulicke & Soffa, Advance Auto Parts, Element Solutions, FTAI Aviation and Andersen Group to improving semiconductor, automotive, specialty-chemical, aerospace and advisory-business fundamentals. The managers exited Kyndryl after deteriorating execution and disclosures, while retaining value-oriented exposure to insurers and other cash-generative businesses outside the AI trade. year-to-date period ended 6/30/26 AAP $2.5BAGO $3.1BANDG $1.1B
- Royce Investment Partners Royce Small-Cap Total Return Fund Manager Commentary Royce Small-Cap Total Return Fund attributes its lag versus the Russell 2000 Value Index largely to stock selection and limited exposure to AI-led technology names. It argues that holdings including Kulicke & Soffa, Advance Auto Parts and Element Solutions benefit from cyclical recoveries or secular demand, while retaining a contrarian focus on cash-generative old-economy businesses. Year-to-Date Through 6/30/26 AAP $2.5BBRSL $1.9BCBZ $3B
- Royce Investment Partners Royce Small-Cap Opportunity Fund Manager Commentary Royce Small-Cap Opportunity Fund retained exposure to semiconductor and AI-infrastructure beneficiaries while selling Applied Optoelectronics and Penguin Solutions at valuation targets. It exited Kyndryl and EPAM, added to OptimizeRx and Tandem Diabetes Care, and shifted capital toward cyclicals, North American energy, cybersecurity, and niche software. first half of 2026 AAOI $11BAORT $1.1BCOHU $3.5B
- Royce Investment Partners Royce Small-Cap Fund Manager Commentary Royce Small-Cap Fund favored Element Solutions, Onto Innovation, MKS, Ultra Clean Holdings, and Arcosa, citing AI-linked process complexity, semiconductor capacity investment, specialty chemicals, and infrastructure demand. It exited PAR Technology, ADMA Biologics, Kyndryl Holdings, and TransMedics Group as execution, balance-sheet, or earnings concerns weakened the original theses, while adding to MAXIMUS. year-to-date period ended 6/30/26 ACA $7.2BADMA $2.3BESI $9B
